Home » Newsletters » BioWorld Science

BioWorld Science

March 23, 2016

View Archived Issues

Vertex describes discovery of DNA-PK inhibitor

GlaxoSmithKline develops a second-generation HCV NS5A replication complex inhibitor

Zymeworks completes acquisition of Kairos Therapeutics

MN-166 receives FDA fast track designation for progressive multiple sclerosis

Bayer Schering Pharma discloses prostanoid FP receptor antagonists

Biolab Sanus Farmaceutica patents cyclic nucleotide inhibitors

HEC Pharm announces prostanoid DP2 receptor antagonists

Samumed divulges Wnt signaling inhibitors

RaQualia and Asahi Kasei Pharma enter new research collaboration agreement

Celyad and Institut Curie to collaborate on immuno-oncology program

Neuropore Therapies' NPT200-11 well tolerated in phase I study

Genisphere and University of Pennsylvania enter research agreement

Eiger BioPharmaceuticals completes merger with Celladon

Pfizer joins the Human Vaccines Project

Santen China and Chongqing Kerui enter a new strategic collaboration

OncoVent, a new company in China focusing on development of cancer immunotherapies

Bristol-Myers Squibb discloses novel HCV NS3 protease inhibitor

Aprecia Pharmaceuticals launches first FDA-approved 3D printed tablets

Lilly's ixekizumab approved in the U.S. for plaque psoriasis

OncoTherapy Science reports completion of phase I/II study of cancer vaccine OTSGC-A24

Alirocumab meets primary endpoint in ODYSSEY ESCAPE trial

BRD4 inhibitors demonstrate preclinical efficacy

bioLytical completes preclinical prototype assay to detect Zika, Dengue and Chikungunya antibodies

Janssen announces more collaborations through its DIA unit

Novel POLG2 variant may be associated with mitochondrial DNA depletion syndrome

AstraZeneca's ticagrelor stroke study misses primary endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...